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Abstract The transmembrane protein gp130 is the common
signalling receptor subunit for the interleukin-6 (IL-6)-type
cytokines. It has recently been shown that the cytoplasmic
domain of gp130 contains a dileucine internalization motif and
that endocytosis of gp130 occurs signal-independent. Here, we
have studied whether gp130 itself undergoes constitutive inter-
nalization or whether its endocytosis is stimulated by formation
of the IL-6/IL-6R/gp130 complex. Using two different assays, we
found that gp130 is internalized independent from IL-6/IL-6R
stimulation. In addition, we show that gp130 is constitutively
associated with the cell surface adaptor complex AP-2. Our
findings strongly suggest endocytosis of gp130 to be constitutive.
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1. Introduction
Polypeptide hormones, growth factors and cytokines acti-
vate intracellular signalling cascades via plasma membrane
receptors. In many cases, ligand binding results in the dimer-
ization of receptor molecules which then triggers activation of
intracellular kinases and phosphorylation of signalling com-
ponents. In addition, many ligand-receptor complexes under-
go endocytosis and degradation within lysosomes. Recep-
tor-mediated endocytosis of signalling proteins serves at
least two important functions: removal of the ligand from
the circulation and modulation of cell surface receptor expres-
sion.
Two modes of internalization have been observed in well-
characterized receptor systems like the insulin and the epider-
mal growth factor receptor: (i) a basal constitutive endocyto-
sis and (ii) a ligand-triggered increased endocytosis depending
on an activated receptor tyrosine kinase which usually results
in a receptor down-regulation [1^4].
Endocytosis of plasma membrane receptors in most cases
occurs via clathrin coated vesicles. Prerequisite for the inclu-
sion into clathrin coated vesicles are amino acid motifs within
the cytoplasmic domain of the receptors that are recognized
by adaptor proteins of which three are currently known, AP-
1, AP-2 and AP-3. Each adaptor complex forms a heterotet-
ramer consisting of two larger and two smaller subunits.
Whereas AP-1 is crucial for the formation of clathrin coated
vesicles at the trans-Golgi network, AP-2 serves this function
at the plasma membrane. The function of AP-3 is currently
unclear since it does not associate with clathrin [5,6]. Two
sorts of amino acid motifs are found as internalization signals,
tyrosine-based motifs and dileucine motifs. Both motifs were
found to interact with the medium chains (W1 and W2) of AP-1
and AP-2, respectively [7,8]. However, for dileucine-based mo-
tifs an interaction with the L-chain of AP-1 has also been
described [9].
In recent years we have studied the endocytosis of interleu-
kin-6 (IL-6), a multifunctional cytokine. IL-6 signals via a cell
surface receptor complex consisting of IL-6, the IL-6 receptor
gp80 (CD126) and gp130 (CD130) (reviewed in [10]). IL-6 ¢rst
binds to gp80 and then induces the dimerization of two mol-
ecules of gp130. Thereby, associated Janus tyrosine kinases
(Jak) are activated and phosphorylate gp130 and transcription
factors of the STAT family. Phosphorylated STATs dimerize
and translocate to the nucleus where they transactivate IL-6
target genes [10^12]. After binding, IL-6 is internalized e⁄-
ciently and surface gp80 is down-regulated [13]. We have pre-
viously demonstrated that the IL-6 signal transducer gp130
contains a dileucine motif within its cytoplasmic domain nec-
essary for the endocytosis of the IL-6 receptor complex [14].
Since gp80 per se is internalized very ine⁄ciently, the ob-
served down-regulation of gp80 after IL-6 stimulation can
be explained by the formation of the ternary receptor complex
in which gp130 not only mediates signal transduction but also
promotes e⁄cient endocytosis [15].
Activation of the Jak/STAT pathway via the IL-6 receptor
complex or agonistic antibodies against gp130 was found not
to be necessary for endocytosis to occur [16]. These ¢ndings
suggested that signalling and internalization are independent
processes. However, currently it is not clear whether gp130
itself undergoes constitutive endocytosis or whether its inter-
nalization is stimulated by formation of the IL-6/gp80/gp130
complex. To answer this question we compared the internal-
ization of free and complexed gp130 using two di¡erent pro-
tocols and studied whether gp130 associates with the plasma
membrane adaptor complex AP-2.
2. Materials and methods
2.1. Reagents
Restriction enzymes and T4 ligase were obtained from Boehringer
Mannheim (Mannheim, Germany). Dulbecco’s modi¢ed Eagle’s me-
dium was purchased from Gibco (Eggenstein, Germany), and fetal
calf serum was from Seromed (Berlin, Germany). Recombinant IL-6
was prepared as described [17]. Soluble human IL-6R (sIL-6R) was
prepared in insect cells infected with recombinant baculoviruses [18].
2.2. Cell culture
COS-7 cells were grown in DMEM, HepG2 cells in DMEM/F12-
Mix, each supplemented with 10% fetal calf serum, streptomycin (100
mg/l) and penicillin (60 mg/l). Ba/F3 cells, a murine pre-B lymphocyte
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line, were cultured in DMEM containing 10% fetal calf serum and 5%
conditioned medium from X63Ag-653 BPV-mIL-3 myeloma cells as a
source of IL-3 [19]. All cells were grown at 37‡C at 5% CO2 in a
water-saturated atmosphere.
2.3. Expression vectors
The vector pSVLgp130 was a kind gift of Drs. Taga and Kishimoto
(Osaka, Japan). The expression vector pCAGGS was kindly provided
by Dr. Hirano (Osaka, Japan); the vector pCAGGS-gp130 was con-
structed by subcloning the XbaI-BamHI fragment of the pSVLgp130
plasmid containing the gp130 cDNA into the XbaI-BglII sites of
pCAGGS.
2.4. Transfections
2U106 COS-7 cells in 0.8 ml DMEM were transiently transfected
with 30 Wg of pCAGGS-gp130 with the Electro Square Porator T820
(BTX, San Diego, CA, USA) using one pulse of 99 Ws and 1500 V.
Cells were processed for cell surface biotinylation two or three days
after transfection when reaching con£uency.
Ba/F3 cells were stably transfected by electroporation of 28 Wg of
pSVLgp130 and 2 Wg of pSV2neo into 3.5U106 cells in 0.8 ml medium
at 200 V and 70 ms. Selection with G418 (1 mg/ml) in IL-3-condi-
tioned medium was initiated 24 h after transfection. Selected Ba/F3
clones were screened for the presence of cell surface gp130 by £ow
cytometry.
2.5. Cell surface half-life measurement of gp130
Ba/F3 cells stably expressing human gp130 were incubated at 37‡C
for di¡erent times in culture medium containing 50 WM cycloheximide
to prevent de novo synthesis of gp130. Subsequently, the cells were
cooled to 4‡C, washed, and cell surface expression of gp130 was
assessed by £ow cytometry.
2.6. Flow cytometry
Ba/F3-gp130 cells were harvested, washed, and resuspended in cold
PBS supplemented with 5% fetal calf serum and 0.1% sodium azide
(PBS/azide); cells were then ¢xed in 2% paraformaldehyde for 20 min
on ice. 1U106 cells in 200 Wl of PBS/azide were incubated with 2 Wg of
the gp130 speci¢c monoclonal antibody (mAb) B-R3 [21] for 30 min,
washed twice, and the gp130-bound antibodies visualized using a 1:50
dilution of an R-phycoerythrin-conjugated anti-mouse IgG-F(abP)2
(Dianova, Hamburg, Germany) for 30 min on ice. Subsequently, cells
were washed and resuspended in PBS/azide. 2U104 cells/sample were
analyzed using a FACScalibur (Becton Dickinson, USA). Mean £uo-
rescence intensity (MFI) was recorded and used in the calculation of
percent antibody binding: (MFI of cycloheximide treatment) divided
by (MFI of cells at time point 0)U100.
2.7. Reversible biotinylation assay
A cleavable biotin analogue, sulfosuccinimidyl 2-(biotinamino)eth-
yl-1,3 dithiopropionate (NHS-SS-biotin, Pierce, USA) was used to
label cell surface proteins [20]. The cells were washed three times
with biotin bu¡er (120 mM NaCl, 20 mM NaHCO3, 1 mM MgCl2,
0.1 mM CaCl2, pH 8.5). NHS-SS-biotin (0.5 mg/ml in biotin bu¡er,
freshly diluted from a frozen stock of 200 mg/ml in DMSO) was
added and labelling was carried out for 45 min. After washing,
warm medium was added and cells were transferred to 37‡C for 10^
30 min. This incubation was performed in the absence or presence of
IL-6 (20 ng/ml) and sIL-6R (1 Wg/ml). For controls and each time
point, one 10-cm diameter dish with 1U107 cells was used; two dishes
of each stimulated and non-stimulated cells were kept on ice. Incuba-
tion was stopped by transferring the cells back to 4‡C. Following a
60-min incubation with a reducing solution (310 mg glutathione in 17
ml H2O, 1 ml of 1.5 M NaCl, 0.12 ml of 50% NaOH, 2 ml of serum)
to remove cell surface-bound biotin, free SH groups were quenched in
5 mg/ml iodacetamide in biotin bu¡er for 30 min. Cell extracts were
immunoprecipitated and analyzed as described below.
2.8. Immunoprecipitations
For immunoprecipitation of biotinylated gp130, surface labelled
COS-7 cells were washed twice with PBS and solubilized for 30 min
in 1 ml of lysis bu¡er (1% Nonidet P-40, 0.5% deoxycholate, 0.1%
SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4). Insoluble material
was removed by centrifugation for 10 min at 12 000Ug. The super-
natants were incubated with 1 Wg of gp130-speci¢c mAb B-S12 [21]
for at least 8 h at 4‡C. Subsequently, the lysates were treated for 2 h
at 4‡C with protein A-Sepharose (5 mg/ml in lysis bu¡er), to which
rabbit anti-mouse IgG was previously bound. After centrifugation of
the immunocomplexes, the Sepharose beads were washed three times
with lysis bu¡er. The samples were heated to 55‡C in non-reducing gel
electrophoresis sample bu¡er, and the eluted proteins were separated
on an SDS-polyacrylamide (7.5%) gel.
For co-immunoprecipitations of gp130 and AP-2, 1U108 HepG2
cells were lysed in 10 ml of lysis bu¡er (50 mM HEPES, 150 mM
NaCl, 0.1% Triton X-100, 10% glycerol, 1 mM EGTA, 1.5 mM
MgCl2, pH 7.5). Ten Wg of mAb B-S12 were then added to the lysates
to precipitate gp130. After incubation with protein A-Sepharose as
described above, the samples were boiled in reducing sample bu¡er
and separated on a 7.5% SDS-polyacrylamide gel.
2.9. Western blotting and immunodetection
The electrophoretically separated proteins were transferred to poly-
vinylidene di£uoride (PVDF) membranes by the semi-dry Western
blotting method. Non-speci¢c binding was blocked with 10% bovine
serum albumin in TBS-N (20 mM Tris-HCl, pH 7.4, 137 mM NaCl,
0.1% Nonidet P-40) for 20 min. The blots were incubated with a
gp130-speci¢c mAb (B-P4 [21]) or a speci¢c antiserum directed against
K-adaptin (Upstate Biotechnology, USA), respectively, at a concen-
tration of 1 Wg/ml in TBS-N for 1 h. After extensive rinsing with TBS-
N, the immunoblots were incubated for 1 h with a horseradish per-
oxidase-conjugated goat anti-mouse or a goat anti-rabbit IgG second-
ary antibody, respectively.
To detect biotinylated gp130, the immunoblot was incubated with
horseradish peroxidase-conjugated streptavidin (Pierce, USA; 1 mg/
ml in TBS-N) for 1 h. The immunoblots were developed using the
enhanced chemiluminescence system (ECL, Amersham Pharmacia
Biotech) according to the manufacturer’s instructions.
3. Results
In order to analyze whether the internalization of gp130 is
constitutive or stimulated by ligand binding, a reversible sur-
face biotinylation assay was performed on COS-7 cells tran-
siently over-expressing the IL-6 signal transducer [20]. Two to
three days after transfection, cell surface proteins were la-
belled with an NHS-SS-biotin at 4‡C. Afterwards cells were
transferred to 37‡C for 10^30 min and then incubated at 4‡C
in a reducing solution resulting in the cleavage of the biotin
label in proteins still located at the cell surface. Gp130 was
immunoprecipitated, separated by SDS-PAGE, transferred to
a PVDF membrane and biotinylation was detected using
horseradish peroxidase-conjugated streptavidin. Fig. 1 shows
a prominent signal for biotinylated gp130 in the control lane
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Fig. 1. Endocytosis of biotinylated gp130 in COS-7 cells. The cell
surface proteins were labelled with NHS-SS-biotin as described in
Section 2. Cells were incubated at 37‡C for di¡erent time points as
indicated. The cells were lysed, and gp130 was immunoprecipitated,
separated on a 7.5% non-reducing SDS-gel, and blotted on a PDVF
membrane, and biotinylated gp130 detected using horseradish per-
oxidase-conjugated streptavidin and the ECL system. Lane 1 repre-
sents non-reduced control cells ; lanes 2^5: unstimulated cells ; lanes
6^9: cells stimulated with IL-6 (20 ng/ml) and sIL-6R (1 Wg/ml).
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(no reduction; lane 1). After reduction this label is almost
completely lost (lanes 2 and 6). Upon incubation at 37‡C an
increasing amount of biotinylated gp130 becomes resistant to
reduction irrespective of whether a ligand (IL-6 and soluble
IL-6 receptor) is present or not, indicating that gp130 is con-
stitutively removed from the cell surface by internalization
(compare lanes 2^5 and 6^9).
In order to corroborate this ¢nding using a di¡erent ap-
proach, we studied the half-life of surface-expressed gp130
in the absence or presence of IL-6/sIL-6R complexes using
£ow cytometry. To this end, we used non-adherent murine
Ba/F3 cells which have been stably transfected with human
gp130 (Ba/F3-gp130) [19]. These cells were incubated with
cycloheximide at a concentration of 50 WM to block further
protein synthesis and cells were either incubated with IL-6/
sIL-6R or left unstimulated. After di¡erent times at 37‡C,
cells were cooled down to 4‡C and processed for £ow cytom-
etry. Fig. 2 shows the time course of the reduction of cell
surface gp130 as measured by the mean £uorescence intensity.
The gp130 signal disappears with a half-life of about 2 h
irrespective of whether a ligand was present or not, supporting
the notion that internalization as well as surface receptor half-
life are ligand-independent.
Recently, it was shown that not only tyrosine-based but
also dileucine-based internalization motifs are recognized by
the adaptor complexes AP-1 and/or AP-2 [7]. Endocytosis of
gp130 is dependent on the dileucine internalization motif iden-
ti¢ed previously [15]. We next studied whether gp130 interacts
with the plasma membrane adaptor AP-2 in HepG2 cells ^
which express gp130 endogenously in considerable amounts
[22]. Gp130 was immunoprecipitated from unstimulated
HepG2 cells and two equal aliquots were analyzed by SDS-
PAGE. After transfer to a PVDF membrane the immunoblot
was developed either using a gp130-speci¢c monoclonal anti-
body or an antiserum directed against the K-subunit (K-adap-
tin) of AP-2. As shown in Fig. 3, a protein of about 100 kDa,
which is speci¢cally recognized by the K-adaptin antiserum,
was co-immunoprecipitated with gp130. Upon IL-6 stimula-
tion, no increased association of gp130 with K-adaptin was
detectable (data not shown).
4. Discussion
In this paper we demonstrated that gp130, the signal trans-
ducer of the IL-6 receptor complex, undergoes constitutive
internalization independent of the presence of a ligand. In
this respect, gp130 more resembles nutrient receptors like
the low-density lipoprotein receptor and the transferrin recep-
tor than other signalling receptors such as insulin receptor or
epidermal growth factor receptor which exhibit an increased
internalization rate upon ligand binding depending on an ac-
tive intrinsic tyrosine kinase [1^4,23,24]. In accordance with
this, we recently found that activation of Janus kinases is not
necessary for gp130 endocytosis to occur [16].
In this study we also demonstrated a constitutive interac-
tion of gp130 with the plasma membrane adaptor AP-2. This
adaptor complex is an important component of clathrin
coated vesicles. It is thought to mediate clathrin coat assembly
by binding to the cytoplasmic tails of proteins containing in-
ternalization signals and recruiting clathrin [5]. Thus, it seems
very likely that the constitutive endocytosis of gp130 occurs
via clathrin coated vesicles. Recently, an association of gp130
with caveolae has been described in the human kidney epithe-
lial tumor cell line TCL-598 [25]. However, this might be a
special situation since in these cells gp130 was found to be
associated with the urokinase-type plasminogen activator
which is bound to the membrane by a glycosylphosphatidyl-
inositol anchor.
The internalization kinetics as determined by the biotinyla-
tion procedure (Fig. 1) and the half-life of total surface gp130
as determined by £ow cytometry (Fig. 2) were distinct.
Although this could re£ect the di¡erent cell types used, it
seems more likely that this observation indicates that internal-
ized gp130 at least in part recycles back to the cell surface.
This behavior is also typical for nutrient receptors where each
molecule was found to recycle many times before it is de-
graded in lysosomes [24]. Interestingly, IL-6/sIL-6R complexes
did not show any signi¢cant e¡ects on the gp130 surface half-
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Fig. 3. K-Adaptin co-immunoprecipitates with gp130 in HepG2 cells.
1U108 unstimulated HepG2 cells were lysed and gp130 was immu-
noprecipitated (IP) as described in Section 2. Equal aliquots were
separated on an SDS-gel and the immunoblot (IB) was developed
using either a gp130 speci¢c mAb (left lane) or an antiserum speci¢c
for K-adaptin (right lane). A protein migrating at the identical posi-
tion was also detected when whole cell extracts were directly immu-
noprecipitated with an anti-K-adaptin antibody (data not shown).
Fig. 2. Cell surface half-lives of gp130 in IL-6/sIL-6R-stimulated (F)
or unstimulated (E) Ba/F3-gp130 cells. Cell surface expression on
cells treated for di¡erent times with 50 WM cycloheximide was as-
sessed by £ow cytometry using mAb B-R3. Time 0 corresponds to a
30-min incubation in cycloheximide containing medium, since this is
the time required for newly synthesized gp130 to reach the cell sur-
face [22]. Antibody binding was calculated as described in Section 2.
The means and S.D. of four independent experiments are shown.
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life suggesting that not only internalization but also recycling
are independent of receptor ligation.
In conclusion, our data indicate that the tra⁄cking of the
IL-6 signal transducer gp130 is largely independent of ligation
and dimerization and thus constitutive.
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